Literature DB >> 20235331

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Josephine H Li1, Xiang Qian Lao, Hans L Tillmann, Jennifer Rowell, Keyur Patel, Alexander Thompson, Sunil Suchindran, Andrew J Muir, John R Guyton, Stephen D Gardner, John G McHutchison, Jeanette J McCarthy.   

Abstract

UNLABELLED: Recently, genetic polymorphisms occurring in the interferon (IFN)-lambda gene region were associated with response to IFN-based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with decreased serum cholesterol and high cholesterol has been associated with increased likelihood to respond to IFN. We sought to determine if the IFN-lambda gene variant was also associated with serum lipid levels in chronic hepatitis C patients. We compared genotypes of the rs12979860 polymorphism, located proximal to the IL28 gene, with serum lipid and apolipoprotein levels in 746 subjects with chronic hepatitis C virus infection, not currently undergoing treatment, using multivariable analysis of variance. Levels of total cholesterol (P = 6.0 x 10(-4)), apolipoprotein B (P = 1.3 x 10(-6)) and low-density lipoprotein (LDL) cholesterol (P = 8.9 x 10(-10)) were significantly higher in subjects carrying the rs12979860 CC responder genotype compared with those with the CT or TT genotype. Levels of triglycerides (P = 0.03), apolipoprotein A-I (P = 0.06), and apolipoprotein E (P = 0.01) were slightly lower in the rs12979860 CC genotype group, whereas levels of high-density lipoprotein cholesterol (P = 0.78) and apolipoprotein C-III (P = 0.74) did not vary by rs12979860 genotype.
CONCLUSION: Our results suggest that low levels of LDL cholesterol in chronic hepatitis C patients may be a marker of host endogenous IFN response to hepatitis C and that subjects with the rs12979860 CC responder genotype may have a lower endogenous IFN response to the virus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20235331      PMCID: PMC2921623          DOI: 10.1002/hep.23592

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  The effect of interferon on the metabolism of LDLs.

Authors:  G Schectman; S Kaul; R A Mueller; E C Borden; A H Kissebah
Journal:  Arterioscler Thromb       Date:  1992-09

2.  Serum lipid pattern in chronic hepatitis C: histological and virological correlations.

Authors:  D Siagris; M Christofidou; G J Theocharis; N Pagoni; C Papadimitriou; A Lekkou; K Thomopoulos; I Starakis; A C Tsamandas; C Labropoulou-Karatza
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

Review 3.  Interferons: from virus inhibitor to modulator of amino acid and lipid metabolism.

Authors:  E C Borden; I B Rosenzweig; G I Byrne
Journal:  J Interferon Res       Date:  1987-10

4.  Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.

Authors:  Jin Ye; Chunfu Wang; Rhea Sumpter; Michael S Brown; Joseph L Goldstein; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

5.  Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b.

Authors:  H Mawatari; M Yoneda; K Fujita; Y Nozaki; Y Shinohara; H Sasaki; H Iida; H Takahashi; M Inamori; Y Abe; N Kobayashi; K Kubota; H Kirikoshi; A Nakajima; S Saito
Journal:  J Viral Hepat       Date:  2009-08-25       Impact factor: 3.728

6.  Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C.

Authors:  G Soardo; M Pirisi; M Fonda; C Fabris; E Falleti; P Toniutto; D Vitulli; L Cattin; F Gonano; E Bartoli
Journal:  J Interferon Cytokine Res       Date:  1995-08       Impact factor: 2.607

7.  Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases.

Authors:  C Ehnholm; K Aho; J K Huttunen; E Kostiainen; K Mattila; J Pakkarainen; K Cantell
Journal:  Arteriosclerosis       Date:  1982 Jan-Feb

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.

Authors:  Mircea Grigorescu; Mihaela Rusu; Daniela Neculoiu; Corina Radu; Alexandru Serban; Mihaela Catanas; Mircea Dan Grigorescu
Journal:  J Gastrointestin Liver Dis       Date:  2007-03       Impact factor: 2.008

10.  Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.

Authors:  Jean Michel Petit; Muriel Benichou; Laurence Duvillard; Valerie Jooste; Jean Baptiste Bour; Anne Minello; Bruno Verges; Jean Marcel Brun; Philippe Gambert; Patrick Hillon
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  50 in total

Review 1.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

2.  The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records.

Authors:  Jessica D Tenenbaum; Victoria Christian; Melissa A Cornish; Rowena J Dolor; Ashley A Dunham; Geoffrey S Ginsburg; Virginia B Kraus; John G McHutchison; Meredith L Nahm; L Kristin Newby; Laura P Svetkey; Krishna Udayakumar; Robert M Califf
Journal:  Am J Transl Res       Date:  2012-07-23       Impact factor: 4.060

Review 3.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

4.  Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C.

Authors:  Shunsuke Sato; Takuya Genda; Katsuharu Hirano; Hironori Tsuzura; Yoshio Kanemitsu; Yutaka Narita; Tetsu Kikuchi; Katsuyori Ijima; Takafumi Ichida
Journal:  Hepatol Int       Date:  2011-04-02       Impact factor: 6.047

5.  Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.

Authors:  Yoshio Aizawa; Kai Yohizawa; Yuta Aida; Haruya Ishiguro; Hiroshi Abe; Akihito Tsubota
Journal:  Mol Cell Biochem       Date:  2011-08-31       Impact factor: 3.396

Review 6.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

7.  IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.

Authors:  Melanie E Garrett; Manal F Abdelmalek; Allison Ashley-Koch; Michael A Hauser; Cynthia A Moylan; Herbert Pang; Anna Mae Diehl; Hans L Tillmann
Journal:  J Hepatol       Date:  2012-10-11       Impact factor: 25.083

8.  Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

Authors:  F A Di Lello; A Caruz; N I Rallon; A Rivero-Juarez; K Neukam; P Barreiro; A Camacho; S García-Rey; A Rivero; V Soriano; C Cifuentes; J Macias; J A Pineda
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-05-29       Impact factor: 3.267

9.  Entry of hepatitis C virus into the cell: a therapeutic target.

Authors:  José Antonio Del Campo; Ángela Rojas; Manuel Romero-Gómez
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

Review 10.  Interferon-λs: special immunomodulatory agents and potential therapeutic targets.

Authors:  Ya-wen Zheng; Hui Li; Jin-pu Yu; Hua Zhao; Shizhen Emily Wang; Xiu-bao Ren
Journal:  J Innate Immun       Date:  2012-11-30       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.